Diagnostic Centre, University Clinic for Development of Innovative Patient Pathways, Silkeborg Regional Hospital, Falkevej 3, 8600 Silkeborg, Denmark.
Department of Clinical Medicine, Aarhus University, Aarhus, Denmark.
Eur Heart J Qual Care Clin Outcomes. 2022 Aug 17;8(5):539-547. doi: 10.1093/ehjqcco/qcab036.
Incident atrial fibrillation (AF) is an adverse prognostic indicator in heart failure (HF); identifying modifiable targets may be relevant to reduce the incidence and morbidity of AF. Therefore, we examined the association between quality of HF care and risk of AF.
Using the Danish Heart Failure Registry, we conducted a nationwide registry-based cohort study of all incident HF patients diagnosed between 2008 and 2018 and without history of AF. Quality of HF care was assessed by seven process performance measures, including echocardiographic examination, New York Heart Association classification, treatment with angiotensin-converting enzyme inhibitors/angiotensin II receptor blockers, beta-blockers, and mineralocorticoid antagonists, physical training, and patient education. In the main analysis, we examined adherence with all measures in a cohort of 25 100 patients (mean age 68.5 ± 13.2 years; 33.6% women). The median follow-up was 3.1 years. Cox proportional hazard regressions estimated the hazard ratios (HRs) with 95% confidence intervals (95% CIs) between the number of fulfilled measures and incident AF. In a multivariable-adjusted analysis with 0 fulfilled performance measures as reference, the HRs (95% CIs) were 1: 0.78 (0.61-1.00), 2: 0.63 (0.49-0.80), 3: 0.53 (0.36-0.80), 4: 0.64 (0.44-0.94), 5: 0.56 (0.39-0.82), 6: 0.51 (0.35-0.74), and 7: 0.49 (0.33-0.73), with a significant decreasing linear trend (P < 0.001).
In patients with incident HF, fulfilment of guideline-based process performance measures was associated with decreased long-term risk of AF. This study supports initiatives to improve the quality of care for patients with HF to prevent incident AF.
阵发性心房颤动(房颤)是心力衰竭(HF)的不良预后指标;确定可改变的靶点可能与降低房颤的发生率和发病率有关。因此,我们研究了 HF 治疗质量与房颤风险之间的关系。
利用丹麦心衰注册中心,我们对 2008 年至 2018 年间诊断为新发 HF 且无房颤病史的所有患者进行了一项全国范围内基于登记的队列研究。HF 治疗质量通过 7 项流程表现指标进行评估,包括超声心动图检查、纽约心脏协会分级、血管紧张素转换酶抑制剂/血管紧张素 II 受体阻滞剂、β受体阻滞剂、盐皮质激素拮抗剂、体力训练和患者教育。在主要分析中,我们对 25100 例患者(平均年龄 68.5±13.2 岁;33.6%为女性)的所有指标的依从性进行了检查。中位随访时间为 3.1 年。Cox 比例风险回归估计了满足的指标数量与房颤发生之间的风险比(HR)及其 95%置信区间(95%CI)。在多变量调整分析中,以 0 个满足的表现指标作为参考,HR(95%CI)分别为 1:0.78(0.61-1.00)、2:0.63(0.49-0.80)、3:0.53(0.36-0.80)、4:0.64(0.44-0.94)、5:0.56(0.39-0.82)、6:0.51(0.35-0.74)和 7:0.49(0.33-0.73),呈显著的线性递减趋势(P<0.001)。
在新发 HF 患者中,符合基于指南的流程表现指标与长期房颤风险降低相关。本研究支持改善 HF 患者治疗质量以预防房颤发生的举措。